SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation System Significantly Reduces Opioid Use in Patients with Low Back Pain, Interim Data Show
Majority of patients treated with SPRINT 60-day PNS therapy also achieved clinically significant reductions in pain intensity, disability and pain interference
Cleveland, Ohio and Kissimmee, Florida – August 21, 2019 – SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, presented interim results today on the safety and effectiveness of the SPRINT® Peripheral Nerve Stimulation (PNS) System when used for the treatment of chronic low back pain. Interim data on the subset of patients taking opioids demonstrated that percutaneous PNS delivered by the SPRINT System for up to 60 days can significantly reduce usage of opioid medication in patients with low back pain. The results also support earlier findings that SPRINT can relieve chronic low back pain, leading to improvement in quality of life and reduction in disability, without a permanently implanted device.
Preliminary results were presented today at the Military Health System Research Symposium (MHSRS) conference in Kissimmee, Florida. Among the cohort of patients with chronic low back pain who were taking opioids, a majority experienced substantial (≥ 50%) reductions in opioid consumption both during treatment and for at least three months following PNS treatment with the SPRINT PNS System. These substantial reductions were seen even among patients with daily baseline opioid consumption ≥ 50 milligram morphine equivalent (rated by the CDC as high-risk for opioid overdose). The reductions in opioid analgesic consumption reported were coupled with clinically significant reductions in average pain intensity, disability, and pain interference. https://www.sprtherapeutics.com/wp-content/uploads/2019/08/MHSRS-2019-LBP-Poster-1.pdf
“We continue to be encouraged with the positive outcomes being achieved with SPRINT PNS when used for chronic low back pain,” said Tim Deer, MD, SPRINT PNS study investigator and President and CEO of the Spine and Nerve Centers of the Virginias. “While these are interim data on a subset of the patients, these latest findings further validate the potential of the SPRINT PNS System to reduce opioid use and the need for a permanently implanted device providing a treatment option that should be considered early in the care pathway.”
About SPRINT® PNS System
The SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device FDA-cleared for up to 60 days in the back and/or extremities for both chronic and acute pain, including post-operative and post-traumatic pain.
The SPRINT PNS System works by implanting a thin leadwire, the MicroLead™, typically under image-guidance, to target a peripheral nerve. The MicroLead is connected to a wearable device that sends small electrical pulses to the nerve for up to 60 days after which time the lead is withdrawn. In multiple studies, the SPRINT PNS System has demonstrated the ability to deliver effective and sustained improvements in pain and function after the MicroLead has been withdrawn. Physicians have prescribed the SPRINT system to treat post-amputation pain, end-stage knee and shoulder joint pain, chronic low back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement and surgical reconstruction (partial listing). Several post-market clinical trials are underway.
About SPR Therapeutics, Inc.
SPR Therapeutics, Inc. is a privately-held medical device company focused on developing, manufacturing and commercializing non-opioid, minimally invasive, neurostimulation device treatment options that improve quality of life. The company is headquartered in Cleveland, Ohio, with additional offices in Maple Grove, Minnesota and Chapel Hill, North Carolina. The company’s SPRINT technology is the only percutaneous Peripheral Nerve Stimulation (PNS) System FDA-cleared to treat both chronic and acute pain. More information can be found at: www.SprTherapeutics.com.
Read the full article at GlobeNewswire.com.
# # #
SPR Contact:
Mark Stultz
Senior Vice President
mstultz@SprTherapeutics.com
612-770-0390
Media Contact:
Helen Shik
Shik Communications LLC
ShikPR@SprTherapeutics.com
617-510-4373
